中文摘要：

目的 研究肝力注射液体外逆转人肝癌细胞5-Fu获得性多药耐药的作用。方法MTT法检测肝力注射液对人肝癌BEL-7402／5-Fu耐药细胞株的增殖抑制率及对5-Fu获得性多药耐药的逆转指数，倒置显微镜及Wright—Giemsa染色观察细胞形态学改变，流式细胞术检测细胞内阿霉素荧光强度。结果 人肝癌BEL-7402／5-Fu细胞株对临床常用化疗药物显示出不同程度的交叉抗药性，肝力注射液（以苦参碱计）在0．230、0．115、0．058mg／mL 3个质量浓度对人肝癌BEL-7402耐药细胞株72h的增殖抑制率分别为（9．25±2．38）％、（8．46±1．90）％、（4．23±2．05）%，对5-Fu的逆转指数分别为5．50、3．83、2．25，肝力注射液在0．230mg／mL质量浓度预处理细胞2h能提高细胞内阿霉素的量约38．61％。结论肝力注射液在体外具有逆转人肝癌细胞5-Fu获得性多药耐药的作用。

英文摘要：

Objective To study the reversal effect on acquired muhidrug resistance （MDR） of human hepatocellular caricinoma （HCC） by Ganli Injection. Methods Proliferative inhibition rate of HCC BEL- 7402/5-Fu cell line and reversal index of 5-Fu acquired MDR were measured by MTT assay. Cell morphological changes were observed under inverted microscope and Wright-Giemsa stain method. Fluorescence intensity of Adriamycin （ADM） was detected by Flow cytometry. Results HCC BEL-7402/ 5-Fu cell line exhibited cross-resistance to general chemotherapeutics in clinic. Proliferative inhibition rates of HCC BEL-7402/5-Fu cell line treated for 72 h by Ganli Injection at the （matrine） concentration of 0. 230, 0. 115, 0. 058 mg/mL were （9.25±2.38）%, （8.46±1.90）%, and （4.23±2.05）%, respectively. The corresponding reversal indexes to 5-Fu were 5.50, 3.83, and 2.25. Pre-treatment of Galli Injection at the concentration of 0. 230 mg/mL for 2 h could increase the accumulation of ADM in cells to 38. 61%. Conclusion Ganli Injection has the effect on reversing 5-Fu acquired MDR of human hepatocellular carcinoma in vitro.